Literature DB >> 2891392

Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment.

B Browne1, S Linter.   

Abstract

There has been a recent renewal of interest in the use of monoamine oxidase inhibitors, but the concurrent administration of narcotic analgesics is often a cause for concern. This review clarifies the different types of MAOI/narcotic interactions and offers guidelines for the use of narcotic analgesics in the presence of MAOIs. The MAOI/pethidine interaction has two distinct forms: an excitatory and a depressive form. Pethidine must never be used in the presence of MAOIs because of the risk of a fatal excitatory interaction. Morphine does not cause this excitatory interaction, and is the drug of choice provided an allowance is made for possible potentiation of the depressive narcotic effect. It is inevitable that strong analgesia will occasionally be required as an emergency measure in patients on MAOIs, and insufficient attention is paid in psychiatric textbooks to the two different types of interactions and their therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891392     DOI: 10.1192/bjp.151.2.210

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  11 in total

1.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 2.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

3.  Approaches to optimal dosing of hexamethylene bisacetamide.

Authors:  B A Conley; M J Egorin; V Sinibaldi; G Sewack; C Kloc; L Roberts; E G Zuhowski; A Forrest; D A Van Echo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 5.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 6.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

7.  Serotonin syndrome due to venlafaxine overdose.

Authors:  R J Daniels
Journal:  J Accid Emerg Med       Date:  1998-09

Review 8.  Dextromethorphan. An overview of safety issues.

Authors:  J L Bem; R Peck
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

Review 9.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 10.  A comprehensive review of rapid-onset opioids for breakthrough pain.

Authors:  Howard Smith
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.